🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Patients with metformin-treated type 2 diabetes predominantly free of kidney disease have similar five-year kidney outcomes when treated with a sulfonylurea, DPP-4 inhibitor, GLP-1 receptor agonist, or insulin in the setting of good #diabetes management. ja.ma/3Othuof

#ERA23: In patients with kidney failure undergoing kidney-replacement therapy, the use of high-dose hemodiafiltration resulted in lower mortality than conventional high-flux hemodialysis. Full results of the CONVINCE trial: nej.md/43TAelt

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity | NEJM. Very exciting time. In my opinion this is a significant advancement in medicine. This will improve access to care. #ada2023 nejm.org/doi/full/10.10…

Identifying and optimizing patient care models in dialysis programs couldn’t be more important given the increasing number of people requiring dialysis. Among the major influencers of success: pre-dialysis care and length of the patient-provider encounter bit.ly/3Xselrp

#ICYMI, an #ICESKDT study by Kevin Yau & team found that in adults taking quetiapine, concurrent use of clarithromycin was associated w/ a greater 30-day risk of a hospital encounter for encephalopathy, falls, or fracture, compared w/ azithromycin. bit.ly/44w1uY2

Congrats also to Kevin Yau @hladunewich for their awesome Nat Comms paper on bivalent SARS-CoV2 vaccines in kidney disease patients. Thankful to be involved, and ++ thanks to all the St. Michael’s Kidney Transplant Unity Health Toronto transplant pts who participated! nature.com/articles/s4146…

Patients with kidney disease have lower immune response to vaccination. This study found in patients with CKD third dose COVID-19 mRNA vaccination with mRNA-1273 elicited higher SARS-CoV-2 anti-RBD levels in comparison to BNT162b2 over a 6-month period bit.ly/CJASN0328

#CJC Review Article: Biology and Clinical Use of Glucagon-Like-Peptide-1 Receptor Agonists in Vascular Protection 👉 onlinecjc.ca/article/S0828-…

There is a lack of randomized controlled trial data regarding differences in immunogenicity of COVID-19 vaccine regimens in CKD populations. This study found third dose COVID-19 mRNA vaccination with mRNA-1273 elicited higher SARS-CoV-2 anti-RBD levels bit.ly/CJASN0328

In a new review Tony K.T. Lam & colleagues outline how the kidney might modulate feeding and body weight through a growth differentiation factor 15-dependent kidney–brain axis, while discussing impact of #obesity on the #kidney Nature Reviews Endocrinology nature.com/articles/s4157…

New content online: Obesity and the kidney: mechanistic links and therapeutic advances dlvr.it/T2jWqF

Meet one of the 43 CIHR REDI awardees! A kidney doctor and Rhodes Scholar, Ayodele Odutayo’s research focuses on clinical trials to improve outcomes for cardiovascular and renal disease. cihr-irsc.gc.ca/e/53821.html Kidney Foundation Women's College Hospital | Research

Check out our new review: Proximal versus distal diuretics in congestive heart failure NDT

Top line FLOW results. A 24% reduction in the composite outcome with both kidney and cardiovascular components contributing #T2D #CKD #kidney #semaglutide ml-eu.globenewswire.com/Resource/Downl…

Featured in our June issue: Tony K. T. Lam & colleagues review the potential mechanisms by which #obesity might influence #kidney function and discuss regulation of body weight by the kidney rdcu.be/dH64n

Great collaboration with ICES McMaster Research and University of Toronto sites highlighting renal outcomes among patients on pomalidomide based regimens in Canada under the great leadership of Abhijat Kitchlu | Onconephrology doi.org/10.1016/j.clml…

My and Neesh Pannu thoughts on the FLOW trial recently published in NEJM ACP Need to make some progress with universal drug coverage, implementation, and mitigation of side effects to improve DKD outcomes. Dialysis trials pending. acpjournals.org/doi/10.7326/AN…

Excited to share our contributions to a special supplement on combination therapy in chronic kidney disease NDT: Upcoming drug targets for kidney protective effects in chronic kidney disease academic.oup.com/ndt/article/40…

Initiating SGLT2 inhibitors in individuals with diabetes, heart failure, or chronic kidney disease who were taking renin-angiotensin-aldosterone system inhibitors (RAASi) was associated with a lower risk of hyperkalemia. ja.ma/4jzcDys

Analysis of data from Ontario #T2D reveals that GLP-1RA initiation was associated with a reduction in all-cause emergency room visits and hospitalizations compared with new use of a DPP4i. diabetesjournals.org/care/article-a…